BACKGROUND: Antiretroviral adherence is worse in women than in men, and depression can influence medication adherence.
D
isturbing evidence documents inequities in the care of HIV-infected women and men. Women are less likely to receive care from an HIV specialty provider 1,2 or antiretroviral therapy. 3 Among persons treated with highly active antiretroviral therapy (HAART), women initiate this therapy later than men 4, 5 and have a lower likelihood of achieving an undetectable level of HIV RNA. 6 Because failure to suppress viral load increases the risk of AIDS and death, 7, 8 the consequences of poor response to treatment are grave. Virologic success from HAART depends on the level of adherence to this demanding regimen. 9, 10 Several preliminary studies have reported poorer adherence to antiretroviral therapy in women than men, 11±15 but differing socioeconomic status by gender may confound these findings. We conducted a populationbased analysis of pharmacy-based adherence to antiretroviral therapy in Medicaid-enrolled drug users where men and women have a similar socioeconomic background. Depression is highly prevalent in drug users 16±19 but may be especially high in HIV-infected drug-using women.
20±21
Since depression has been linked to poor medication adherence in studies of general populations, 22 it is possible that it may be a contributing factor to women's poorer adherence. We also expected to find that mental health services would show a beneficial association with adherence in both women and men. We further hypothesized that regular drug treatment would be associated with improved adherence because active drug abuse has been associated with poor adherence to antiretroviral therapy. 23±24 If women had poorer access to or benefit from drug treatment, this might also contribute to gender inequities in adherence. Finally, HIV-focused care from providers under contract to New York State to deliver HIV care and supplementary services to Medicaid enrollees has been associated with improved adherence to antiretroviral therapy. 25 We hypothesized possible gender differences in receipt of this care might contribute to gender inequities in adherence.
METHODS

Study Population
We studied HIV-infected drug users enrolled in New York State (NYS) Medicaid in federal fiscal year 1997. Data were drawn from longitudinally linked Medicaid claims for outpatient physician, clinic, inpatient, and pharmacy services in 1996±1997. We identified Medicaid claims associated with illicit drug use, HIV infection, and AIDS using previously tested algorithms developed by our group. 26±27 The algorithm to screen claims for evidence of drug use searches for International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for heroin, cocaine, amphetamine, or unspecified illicit drug dependence or abuse; for Medicaid services (or rate codes) for methadone treatment or medically supervised substance abuse treatment; and for Diagnosis-Related Groups (DRGs) for inpatient illicit drug detoxification. From National Drug Codes on pharmacy claims, we identified all Food and Drug Administration± approved antiretroviral drugs. Our study cohort was drawn from 59,104 individuals enrolled in New York State Medicaid for at least 10 months in 1997. Of this group, 11,427 (19%) met our HIV case finding algorithm. HIV-infected persons met at least one of the following criteria: 1) pharmacy claim for antiretroviral drug(s); 2) any inpatient stay with a diagnosis of an AIDSdefining condition or HIV-related DRG; or 3) at least 2 occurrences >30 days apart of a) an outpatient physician or clinic visit with an HIV-related or AIDS-defining diagnosis, b) an HIV outpatient care rate code, or c) inpatient stay for an HIV-related condition such as pneumonia.
The sensitivity and specificity of these approaches for identifying drug users and HIV-infected persons have been evaluated in a chart review validation study at Montefiore Medical Center that has been reported previously. 26±27 The drug user algorithm had a sensitivity of 0.86 and a specificity of 0.87 for identifying drug abuse. When misclassification in charts due to drug users receiving drug treatment services from other locations was taken into account, these characteristics rose to 0.87 and 0.97, respectively. The sensitivity and specificity were 0.96 and 1.0, respectively, for detecting HIV infection. From the HIV-infected group (N = 11,427), we excluded 3,424 persons with no antiretroviral therapy claims in 1996 and 1997, 163 pregnant or peripartum women, on the basis of diagnoses and services received in 1997 because of changes in care, and 12 persons without demographic data. Of the remaining 7,840 subjects, we excluded 1,315 persons with fewer than 60 days of combination antiretroviral therapy, 821 persons with fewer than 180 days from initiation of combination therapy until last prescription(s) in 1997, and 601 persons whose antiretroviral therapy was started in the last 90 days of 1997. These criteria allow sufficient time to evaluate adherence to combination antiretroviral therapy using the pharmacy-based measure. 28 Our final study population totaled 5,103 persons.
Pharmacy-based Measurement of Adherence
To assess adherence, we employed an approach that we used in several other similar studies. 25, 29 After identifying antiretroviral drugs from National Drug Codes, we examined adherence among persons prescribed at least 2 drugs concurrently for at least 60 days of 180 days or more on therapy. Adherent subjects needed to have a sufficient amount of prescribed antiretroviral drug(s) to cover at least 95% of days from the first filled prescriptions for combination therapy in 1997 until the end of the last filled prescription(s) in that year. We ascertained the number of days covered by prescribed drug from the``days supply'' field on the claim. In other analyses, we found that the calculated number of days covered based on counting the number of pills and the dose provided differed by only a mean of 2.1 days (SD 13.5) from the``days supply'' field on the claim. 25 To avoid counting erroneous claims, we considered only 1 claim when duplicate claims appeared from 1 pharmacy for the same amount of a drug on the same day (<1% of antiretroviral claims). After a patient had received at least 2 weeks of outpatient antiretroviral therapy, we counted inpatient days as continuing this initiated therapy because we lacked inpatient pharmacy data. When a new drug was prescribed, we gave credit for days potentially covered by the discontinued antiretroviral drug, because a patient might take it until it was finished. Persons prescribed more than 2 drugs concurrently needed to demonstrate adherence to at least 2. The denominator in the calculation of adherent days excluded short gaps in Medicaid eligibility in 1997. The average duration from first to last prescribed antiretroviral therapy in 1997 for the study population was 321 days (SD 55) and the average duration of combination therapy was 241 days (SD 84).
Classification of Outpatient Patterns of Care
Regular drug treatment was defined as care from a single methadone or medically supervised, drug free (Title 1035) clinic for at least 6 contiguous months of nonhospitalized days in 1997 as recommended for effective treatment. 30, 31 At least 3 weekly drug treatment claims per month were required to indicate ongoing care, allowing for 1-week lapses. In infrequent instances in which providers submitted daily drug treatment claims, 15 or more such claims from the same provider in a 30-day interval indicated care for that month. Office physician care was not considered because only a small fraction of office physicians dispense methadone. A regular source of medical care for a study subject was defined as a clinic or physician visited at least twice as an outpatient during 1997 and delivering >35% of all outpatient encounters with primary care, obstetricsgynecologists, or medical subspecialties in that year. 2 These providers could be clinics, group practices, or individual physicians. For ties, a previously developed hierarchy of specialties was used to select 1 provider (i.e., primary care, followed by HIV-related specialties [i.e., infectious diseases, hematology/oncology, allergy/ immunology], obstetrics-gynecology, and other medical subspecialties). 2 We also examined the receipt of at least 2 outpatient encounters in 1997 with clinics or private physicians with an agreement with the State to offer HIVrelated services and expertise (HIV enhanced rate care) in exchange for higher Medicaid payment rates, or with a provider in infectious diseases. 32, 33 We specified at least 2 visits for such care to be able to potentially influence adherence. Finally, we created a variable for at least 2 visits in 1997 to a psychiatric clinic or a private psychiatrist. As with HIV enhanced rate care, 2 or more visits for psychiatric care were viewed as a minimum to affect adherence. To identify persons prescribed antidepressant therapy, we searched for the appropriate National Drug Codes from the NYS Medicaid Management Information System (5-digit) therapeutic codes and/or the FirstDataBank± Medispan formulary therapeutic classification system. We created an indicator for at least 1 filled prescription for antidepressant therapy. We did not require multiple claims for therapy even though more than 1 month of antidepressant treatment is necessary for effective treatment, 34 because this served as another measure of adherence to pharmacologic therapy and was highly correlated with adherence to antiretroviral therapy.
Other Study Variables
Medicaid eligibility files offered age, gender, and NYS region of residence. Residence was classified from ZIP codes as rural, small city, upstate urban, New York City suburb, or New York City. NYS Medicaid files do not contain reliable data on ethnicity. Data on comorbid conditions were also obtained from ICD-9-CM codes on inpatient and outpatient claims files in 1997. We created an indicator for depression based on an approach used by Sambamoorthi et. al. 35 in an analysis of health care utilization of HIV-infected persons that searches for the following diagnoses: major depressive disorder; depressivetype psychosis; neurotic depression; depressive reaction (brief or prolonged); and depression not otherwise specified. To identify persons with advanced HIV infection, we created a flag for patients who had been diagnosed with an AIDS-defining condition. An indicator was also created for chronic diseases other than HIV (i.e., diabetes, hypertension, asthma, sickle cell anemia) that are prevalent in this population. We also created an indicator for acute infections including: septicemia, pneumonia, chronic cutaneous ulcers, endocarditis, osteomyelitis, meningitis, pyelonephritis, and pelvic inflammatory disease.
We also identified specific types of illicit drug and alcohol abuse or dependence. Illicit drug abuse was classified as: drug dependence of unspecified type; heroin or cocaine abuse or dependence; or other drug abuse or dependence (i.e., amphetamine, hallucinogens, marijuana, barbiturates). Acute drug-related events included: drugrelated psychosis; overdose; staphylococcal abscess, myocarditis or sepsis; cellulitis; chest pain or acute myocardial infarction; stroke; intracranial/intraspinal abscess; seizures; nephritis; or rhabdomyolysis. This set of conditions was identified by an expert panel and review of the literature on drug-related complications. Alcohol abuse or dependence was identified by a separate indicator from diagnosis codes (Table 1) .
Analyses
Analyses were performed using Statistical Analysis Software, version 8.0 (SAS, Inc., Cary, NC). We first examined bivariate associations between all covariates and adherence in 1997 for men and women separately. We also conducted bivariate comparisons of the use of the health services of interest by gender. We were also interested in examining differences by depression status, so we examined bivariate associations of all covariates by gender among those with and without depression diagnosed in 1997. Because the effects of health care delivery variables differed by diagnosed depression status, we estimated separate multivariate models for persons with and without depression and within each of these groups by gender. All multivariate models included demographic, clinical, and health care covariates regardless of the significance of their bivariate associations with adherence.
A significant interaction (P < .05) was observed between regular medical care and regular drug treatment and HIV-focused care, respectively. However, neither interaction changed the finding that regular medical care and HIV-focused care did not have significant independent effects on adherence and, therefore, are not reported. An interaction of borderline significance (P = .06) between psychiatric therapy and antidepressant use did show different effects by gender and depression status and is reported using 4-part dummy variables
The P value for the Hosmer-Lemeshow statistic for the full model was .90 and for the separate models was .43 (women with depression), .98 (women without depression), .73 (men with depression), and .11 (men without depression). These statistics indicate generally very good fit. Although the fit for the model of men without depression is less adequate, we found effects similar to those in the model for women without depression, making us less concerned about the poorer fit.
RESULTS
Our pharmacy-based measure indicated that 22% of the study population was adherent to combination antiretroviral therapy at a 95% level. Less than one fifth of women were adherent compared with one quarter of men (P < .001) ( Table 1) . More women were diagnosed with depression than men (34% vs 29%, respectively; P < .001). Surprisingly, adherence was greater in persons of both genders who were diagnosed with depression. In women, adherence was significantly poorer for those with heroin or cocaine abuse. In men, adherence was greater for those residing in New York City and worse for those who developed acute infections such as pneumonia. 250 Turner et al., Health Care Delivery With Antiretroviral Adherence JGIM Women and men did not differ significantly in receipt of mental health care, regular drug treatment, or regular medical care. However, women were slightly more likely to receive HIV-focused care (77% vs 74%, respectively; P = .006). We examined the association of depression and receipt of these health care services with adherence further among drug users in the cohort who were diagnosed with depression (Table 2 ). Most women (84%) and men (81%) in this subset received either psychiatric care or antidepressant therapy. In these groups, adherence was not significantly associated with any of the health care services, with the exception of a positive association of greater adherence for men with depression in regular drug treatment. Table 3 shows the distribution of these health care services and association with adherence among persons without a depression-related diagnosis. Of note, one third of this group received mental health treatment. We observed that, in both genders, psychiatric care and/or antidepressants were not associated with significantly higher proportions of adherent patients. Similar to the group with depression, the only significant association in this subset was a higher proportion of adherence in men who received regular drug treatment.
After adjustment for patient demographic, substance abuse, clinical, and health care factors, an overall model of the entire study cohort showed that women had significantly lower adjusted odds of adherence than men (odds ratio [OR], 0.67; 95% confidence interval [95% CI], 0.58 to 0.78). In a model of only persons diagnosed with depression, the adjusted odds of adherence were significantly increased for those with regular drug treatment or who received psychiatric care with or without antidepressant therapy, compared to those with neither (Table 4 ). In separate models by gender among persons diagnosed with depression, the effect of regular drug treatment was significant only in the men. On the other hand, the adjusted odds of adherence were 90% greater among those women with depression who received both psychiatric care and antidepressant therapy, compared with those receiving neither type of care but only 26% greater in men. This association was weaker in the model including only men with depression, but the confidence interval substantially overlaps that from the model for women with depression. The favorable effect of psychiatric care alone was similar in women and men but did not achieve statistical significance in separate models by gender. A smaller favorable association was observed for antidepressant therapy alone but was also not statistically significant. Among persons without the diagnosis of depression, longitudinal drug treatment showed a significant positive association again only for men (Table 5 ). After adjustment, antidepressant therapy had a small but significant positive association that was similar by gender. Psychiatric care had a somewhat stronger favorable association with adherence for women without diagnosed depression than for men in this subgroup. We created an 8-part dummy variable for the interaction of gender (2 levels) and psychiatric care and antidepressant medication (4 levels) and set the reference as men without diagnosed depression and without mental health care to evaluate whether women without diagnosed depression and without mental health care had lower adjusted odds of adherence. In this model (not shown), women without mental health care had significantly lower adjusted odds of adherence (OR, 0.65; 95% CI, 0.51 to 0.82), while the adjusted odds ratios for the groups of women with psychiatric care and/or antidepressant therapy did not differ significantly. We suggest that a substantial fraction of women in the group without diagnosed or treated depression might have mood disorders affecting adherence.
DISCUSSION
HIV-infected women appear to be particularly vulnerable to experiencing depressive symptoms. 36 Persistent * Also adjusted for: gender (in overall model); age; residence; chronic non-HIV medical condition; acute infection, AIDS or chronic HIV-related complication; acute illicit drug±related complication; drug dependence; heroin or cocaine abuse/dependence; other drug abuse/dependence; alcohol abuse/dependence or acute alcohol-related complication. y Adherence defined as >95% of days covered by at least 2 antiretroviral drugs from initiation of combination therapy in 1997 until the end of the year. CI, confidence interval.
JGIM
depression in women has been associated with significantly poorer survival 37 that may reflect deficiencies in adherence to antiretroviral therapy among depressed women. In this study, we examined the effect of gender, depression, and health care services on adherence in a population-based cohort of Medicaid-enrolled drug users who were at increased risk of deficiencies in adherence. 23±24 Indeed, the overall adherence rate in this cohort was a dismal 22% over an average of 8 months, according to a pharmacybased measure using a 95% cut point. As expected, we found that women had adjusted odds of adherence to antiretroviral therapy that were one third lower than that of men. This finding is unlikely to be confounded by socioeconomic differences present in the other large U.S.-based studies of gender differences in antiretroviral adherence. 11, 12 Our Medicaid-enrolled population included persons who met New York State requirements for eligibility, which are relatively generous compared to the rest of the nation but still not much above federal poverty level. Thus, all of our study population was indigent.
However, contrary to our prior hypotheses, we found that the diagnosis of depression, based on administrative data, was associated with improved adherence in this cohort. However, most of the persons who were diagnosed with depression in this cohort also received mental health services. Mental health services had favorable associations with adherence that were stronger in women than in men. Women with a diagnosis of depression who received psychiatric care in combination with antidepressant therapy had nearly 2-fold greater adjusted odds of adherence than depressed women without either form of care. A synergistic effect of psychotherapy with pharmacotherapy has been described in general populations. 38 Although receipt of regular drug treatment did not differ by gender, men in this cohort had significantly higher adjusted odds of adherence when they received regular drug treatment regardless of depression status. We predicted that regular drug treatment would have a favorable effect on adherence because ongoing substance abuse is strongly associated with poorer adherence. 39 It is possible that men also take more advantage of mental health services available through some drug treatment programs than do women. 40 In both women and men with depression, psychiatric care alone was associated with approximately 50% greater adjusted odds of adherence, whereas antidepressant therapy alone showed positive but nonsignificant effects. In a study of over 1,000 depressed patients, the majority of both women and men preferred counseling over antidepressant therapy, but that study did not examine response to therapy. 41 In a small study of antidepressant therapy in depressed HIV-infected women, Ferrando et al. reported that women often refused participation because they preferred counseling and, of those enrolled, only 60% completed the 8-week study, in part because of frequent side effects. 42 Similar problems with acceptance, persistence, and side effects were observed in a randomized trial of antidepressant therapy in primarily non-drug-abusing HIV-infected men with depression. 43 Therefore, is possible that our cohort did not persist with treatment for depression long enough to demonstrate a benefit in regard to improved adherence. Another potential reason that persons diagnosed with depression in this cohort had better adherence may be the presence of undiagnosed and untreated depression in the group without a depression-related diagnosis. Although approximately one third of our study cohort had a diagnosis compatible with depression or dysthymia, the prevalence of depression was likely even higher. Brienza et al. reported that 54% of persons in a needle exchange program and 42% of those in a methadone maintenance treatment program met criteria for major depression using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. 16 Moore et al. reported that over 65% of HIVinfected women with recent injection drug use or cocaine abuse in a 4-city study screened positive for depressive symptoms on the Center for Epidemiologic Studies Depression Scale. 21 In support of the possibility that some patients in the group without diagnosed depression were actually depressed, we observed a small but significant benefit of antidepressant therapy on adherence in this subset. Although it is possible that these patients were taking these drugs for other indications, such as using imipramine for neuropathy, this type of alternative indication is likely to be infrequent. It is likely that patients or providers may be loath to give a patient the diagnosis of depression, given the stigma associated with this condition. 44 We were surprised to find that neither having regular medical care nor having HIV-focused medical care was associated with improved adherence. We previously reported that more intensive antiretroviral therapy, including HAART, was more likely in drug users treated by providers delivering HIV-focused care. 27 In a cohort of postpartum HIV-infected women, adherence was significantly greater in those who received HIV specialty care. 25 Similarly, adherence was improved in HIV-infected persons in Canada who received care from a more experienced provider. 13 It is possible that drug users have a greater need of adjunctive services such as psychiatric and drug treatment to improve adherence. This study uses a pharmacy-based measure of adherence as in several earlier analyses conducted by our group. 25, 29 This pharmacy-based methodology has the distinct advantage of permitting population-based research 45 and has been applied, for example, in studies of large populations using lipid-lowering medications. 46 For this analysis, we studied only subjects who had been prescribed combination antiretroviral therapy for more than 2 months, as recommended by experts in pharmacy-based measures of adherence. 28 This type of pharmacy-based measure is based on the straightforward premise that when an individual does not receive timely refills of a drug from the pharmacy, she or he is either not taking medication between refills or missing doses such that a given prescription lasts longer than it should. Additional strengths of this approach are that it is not susceptible to reporting bias or tampering. 47 Admittedly, this measure does not take into account the daily timing of taking pills. However, a similar approach to determining adherence that was applied to 266 HIV-infected persons treated with HAART that found that 36% were adherent and that the adherent group had significant reductions in HIV RNA level. 48 A Canadian study of nearly 900 HIV-infected persons applied a pharmacy-based measure and found a linear association between increasing levels of adherence and viral load suppression. 49 A pharmacy claims±based approach to measuring adherence is possible only in settings in which all medications are covered by a single payer as in Medicaid, the Veterans Administration, or a universal health care system, as in Canada. We could not evaluate our approach to measuring adherence because of strict confidentiality agreements that permit analysis of Medicaid claims data. We were only able to conduct a validation study of our case finding methodology through a special agreement with one location at the start of this study.
In this study, we required a high level of adherence of at least 95% of days simultaneously covered by 2 or more prescribed antiretroviral agents in those prescribed combination therapy for at least 2 months. Using a similar pharmacy-based measure, Low-Beer et al. reported that viral load suppression to <500 copies/mL was achieved in 85% of persons who were adherent at a 95% to 100% level, compared with only 64% of persons adherent at a 90% to 95% level. 49 Unfortunately, less than one fourth of the drug users in this cohort were adherent at the 95% level over an 8-month period. Few other studies have used as long a time frame to assess adherence for comparison. However, Arnsten et al. reported a mean of 38% adherence using electronic monitors over a 6-month study period in a cohort of drug users. 24 To identify persons with depression, we employed a methodology that was previously used by Sambamoorthi et al. to a study health care service utilization of HIVinfected persons in New Jersey. 35 In their analysis of 5,559
HIV-infected Medicaid enrollees in New Jersey, these authors found that women and drug users were more likely to be diagnosed with depression on claims. The face validity of this approach is supported by their observation that persons treated for depression were more likely to receive appropriate services. However, as noted previously, the specificity of this approach is high but the sensitivity is likely limited in a cohort of drug users with a high prevalence of depression. This observational study cannot prove causation. Persons who are sufficiently organized to receive psychiatric care or see a physician to be diagnosed with depression might also be more organized in taking medications. After adjustment, we found that women without diagnosed depression or any mental health treatment had significantly poorer adjusted odds of adherence then men without diagnosed depression or mental health treatment. This group of women might have had a high prevalence of depression but been unwilling to receive treatment or even to recognize that they had a problem with depression. We cannot be sure how our results would change if we could include women who had depression that was not diagnosed with the women who were diagnosed with depression. Another limitation of our study is our use of data from the later 1990s. Since that time, both providers and patients have gained more experience with combination antiretroviral therapy and regimens have been simplified somewhat. Current levels of adherence may be better than we observed.
In focus groups, HIV-infected substance-abusing women readily acknowledge the detrimental effects of their own depression and others' negativism and as well as``drinking and drugging'' on antiretroviral adherence. 49 In their review of HIV infection in women, Hader et al. emphasized the need to address mental health issues to improve outcomes of HIV-infected women. 36 Our study supports the benefit of mental health care to adherence to antiretroviral therapy by drug-using women who are diagnosed with depression according to administrative data. In addition, we observed an important benefit of regular drug treatment to antiretroviral adherence in drug-abusing men. Given the critical role that adherence plays in successful treatment of HIV, these findings have important clinical and policy implications for the treatment of one of the most challenging HIV-infected populations.
